Sign in

You're signed outSign in or to get full access.

Nat Y Chan

Director at Healthcare AI Acquisition
Board

About Nat Y Chan

Independent Director (age 37) since December 28, 2023; Australian‑qualified Chartered Accountant with an Executive MBA (Kellogg/HKUST) and a Bachelor of Economics (Macquarie University). Serves as Audit Committee Chair and SEC-designated “audit committee financial expert.” Core credentials span retail/e‑commerce finance and governance, including CFO roles in China; tenure at HAIA dates from his appointment in late 2023 .

Past Roles

OrganizationRoleTenureCommittees/Impact
Richemont China (Shanghai)Chief Financial OfficerSince May 2014Finance leadership; governance over retail/e‑commerce operations
Burberry (Shanghai) Trading Co. Ltd.Finance/leadership (prior role)Not disclosedNot disclosed
Sac & Co Holding LimitedFinance/leadership (prior role)Not disclosedNot disclosed

External Roles

OrganizationRoleTenureCommittees/Impact
Fengmao Trading (Shanghai) Co. Ltd. (Richemont–Alibaba JV)Board DirectorNot disclosedE‑commerce JV governance experience

Board Governance

  • Independence: Board determined Nat Y Chan is independent under Nasdaq and SEC rules; independent directors hold regular sessions .
  • Committee assignments:
    • Audit Committee: Chair; financially literate; designated “audit committee financial expert” by the Board .
    • Compensation Committee: Member (chair is Manuel C. Menendez III) .
    • Corporate Governance & Nominating Committee: HAIA established; composed entirely of independent directors (member specifics not disclosed) .
CommitteeRoleKey Responsibilities
AuditChairAuditor oversight, rotation, independence; pre‑approve audit/non‑audit services; compliance monitoring; review/approve payments to affiliates
CompensationMemberCEO/EO pay oversight; incentive/equity plans; director remuneration review; may retain independent advisors
Gov/NominatingIndependent compositionEstablished per Nasdaq; member details not disclosed

Fixed Compensation

ComponentAmountNotes
Annual retainer (cash)$0No cash compensation to directors prior to business combination
Committee chair/member fees$0Not paid prior to business combination
Meeting fees$0Not paid prior to business combination
Administrative feeN/AFormer sponsor admin fee waived; new sponsor charges no fee

Performance Compensation

MetricTargetActualNotes
Performance equity (RSUs/PSUs)Not applicableNot applicableNo director equity awards disclosed pre‑combination
Bonus metrics (revenue/EBITDA/TSR/ESG)Not applicableNot applicableNo performance-based pay disclosed

Other Directorships & Interlocks

CompanyRoleOverlap/Interlock Risk
Fengmao Trading (Shanghai) Co. Ltd.Board DirectorE‑commerce JV in China; not a disclosed HAIA counterparty
Richemont ChinaCFO (management role)External fiduciary obligations noted; potential corporate opportunity conflicts mitigated by HAIA charter renunciation provisions

Expertise & Qualifications

  • Chartered Accountant (Australia); CFO experience in large retail/e‑commerce operations; SEC “audit committee financial expert” designation .
  • Executive MBA (Kellogg/HKUST) and Bachelor of Economics (Macquarie) .
  • Experience in audit oversight, controls, and cross‑border governance through China‑based leadership roles .

Equity Ownership

HolderClass B SharesClass A SharesVoting Control
Nat Y Chan<1% beneficial ownership (none disclosed)

Notes:

  • Initial shareholders (sponsor and former sponsor) collectively hold the majority of voting power; individual directors, including Chan, show no reportable personal holdings .

Governance Assessment

  • Strengths:

    • Independent audit leadership: Chan chairs the Audit Committee, with SEC “financial expert” designation—strong signal for financial oversight quality .
    • Tight audit committee remit: pre‑approval of audit services, monitoring compliance with IPO terms, and review of payments to affiliates reduces related‑party and control risks typical of SPACs .
    • Conservative pay posture: no cash/equity compensation pre‑combination; minimizes pay‑for‑performance misalignment risk during target search phase .
  • Risks / Red Flags:

    • Sponsor control: initial shareholders control an overwhelming voting stake, enabling proposal passage irrespective of public float—dilutes independent influence (95% cited in proxy Q&A) .
    • Market venue change: HAIA securities delisted from Nasdaq and trade on OTC (HAIAF/HAIUF/HAIWF), heightening liquidity and governance scrutiny risk .
    • Going concern/work capital pressure: minimal cash outside trust and reliance on sponsor loans; board faces pressure in oversight of financing extensions .
    • Corporate opportunity renunciation: charter waives HAIA’s expectancy in certain opportunities; directors hold external fiduciary duties (e.g., Chan at Richemont), increasing conflict navigation complexity .
    • Minimal ownership alignment: Chan has no disclosed equity stake; alignment relies on reputation and committee performance rather than skin‑in‑the‑game .
  • Contextual transaction risk:

    • Proposed combination (Leading Partners/Leading Group) introduces cross‑border/CFIUS sensitivities; board/committees must oversee regulatory diligence and financing/redemption mechanics robustly .

Overall: Chan’s audit leadership and independence underpin board effectiveness amid SPAC‑specific control dynamics. Key investor confidence levers will be rigorous audit committee execution (auditor independence, affiliate payment reviews), transparent conflict management under the charter’s corporate opportunity framework, and enhanced communication around liquidity/redemption and OTC governance constraints .